Naltrexone does reduce appetite, but not in the straightforward way most people imagine. Rather than suppressing the physical sensation of hunger the way some medications do, naltrexone primarily dulls the rewarding pleasure you get from eating, especially from highly palatable foods like sweets and fatty snacks. On its own, naltrexone produces modest weight loss. Its real impact on appetite and body weight shows up when it is paired with bupropion, a combination that works on two brain systems simultaneously and is sold under the brand name Contrave. Understanding which version of “naltrexone for weight loss” actually delivers, and for whom, matters if you’re weighing your options.
How Naltrexone Changes the Way Food Feels
Naltrexone is an opioid antagonist, which means it blocks opioid receptors in the brain. Those receptors are best known for their role in pain relief and addiction, but they also play a central part in how much pleasure you derive from eating. Your brain’s endogenous opioids help regulate what researchers call the hedonic aspects of food: taste enjoyment, the craving for a second cookie, the pull toward rich and sweet foods. By blocking those receptors, naltrexone interferes with the reward signal that food sends through the mesolimbic dopamine pathway.
The effect is more targeted than a general appetite suppressant. Studies using opioid antagonists have found that they suppress intake of sugar solutions more effectively than plain water, and they reduce preference for sweet-tasting solutions altogether.1PubMed Central. The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior In brain imaging work, naltrexone decreased reward-related activation in the caudate and dorsal anterior cingulate cortex when participants were exposed to chocolate, and it simultaneously increased aversion-related activity in the amygdala and insula when they tasted something unpleasant.2PubMed. Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity In plain terms, naltrexone made the appealing food less appealing and the unappealing food slightly more aversive.
This is a meaningful distinction. Naltrexone does not make you feel full faster or reduce the growling-stomach kind of hunger. It changes the emotional and motivational pull that certain foods exert. If you tend to overeat because the food just tastes too good to stop, naltrexone goes after that specific drive.
Naltrexone Alone Produces Modest Results
When researchers have tested naltrexone as a standalone weight-loss treatment, the numbers are real but unspectacular. A systematic review of naltrexone monotherapy found that participants lost an average of about 3.4 kilograms over the study period, while placebo participants actually gained weight.3PubMed Central. Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review That is meaningful for someone’s health, but it is not the dramatic result many people hope for from a prescription medication.
Part of the reason naltrexone’s solo performance is limited has to do with a built-in feedback loop in the brain. Naltrexone stimulates a group of neurons in the hypothalamus called POMC neurons, which help suppress appetite. But those same neurons release beta-endorphin, an opioid peptide that circles back and dampens the very signal that was just activated. So naltrexone ends up partially undoing its own appetite-suppressing effect. This is where bupropion enters the picture.
Why the Combination With Bupropion Works Better
Bupropion, an antidepressant and smoking-cessation drug, independently stimulates those same POMC neurons through a different pathway. When you add naltrexone to bupropion, the naltrexone blocks the opioid-driven autoinhibition that would normally limit POMC activation.4PubMed Central. Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea The result is a sustained appetite-suppressing signal that neither drug achieves well on its own. The combination acts on two systems at once: the hypothalamic hunger-regulation pathway and the mesolimbic reward pathway that drives cravings.5PubMed Central. Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Brain imaging studies have confirmed that this dual action shows up in measurable neural changes. After four weeks of treatment, participants taking naltrexone/bupropion showed blunted hypothalamic reactivity to food cues, meaning the brain’s hunger center responded less intensely to pictures of food. At the same time, activity increased in brain regions involved in self-control and internal awareness, including the anterior cingulate cortex and insula.6International Journal of Obesity. Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues The combination also altered functional connectivity patterns: connectivity between parietal regions and the dorsal anterior cingulate and insula was strengthened, and changes in a frontal brain region correlated with improved craving control scores.7International Journal of Obesity. Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity In other words, the drug combination was not just reducing how rewarding food felt but also boosting the brain circuits that help you say no.
Weight Loss in Clinical Trials
The combination has been tested in several large phase 3 trials. In the COR-I trial, participants taking the higher dose (naltrexone 32 mg plus bupropion 360 mg daily) lost an average of about 6.1% of their body weight over a year, compared to 1.3% in the placebo group.8The Lancet. Effect of a combination of sustained-release naltrexone and sustained-release bupropion on weight loss in overweight and obese adults (COR-I): a randomised, placebo-controlled trial Nearly half of the people on the higher dose lost at least 5% of their body weight, compared with about 16% on placebo. The COR-II trial showed similar results: about 6.4% weight loss over 56 weeks versus 1.2% for placebo, and roughly half of treated participants crossed the 5% threshold.9PubMed Central. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
Pooling the four major phase 3 trials, the placebo-subtracted weight loss was about 4.7%, with improvements in waist circumference, triglycerides, HDL cholesterol, fasting insulin, and insulin resistance in most trials.10PubMed Central. Naltrexone/Bupropion: An Investigational Combination for Weight Loss and Maintenance When the medication was combined with intensive lifestyle counseling and a calorie-reduced diet, weight loss approached about 11% of total body weight, compared to roughly 7% for placebo with the same lifestyle intervention.11PubMed Central. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives That gap illustrates something important: the drug works with lifestyle changes, not as a replacement for them.
How It Stacks Up Against Other Weight-Loss Medications
Naltrexone/bupropion is one of several FDA-approved options, and it sits in the middle-to-lower tier for raw weight loss compared to newer medications. A comparative analysis found that semaglutide (Wegovy) produces about 13.7% average weight loss, phentermine/topiramate (Qsymia) about 9.1%, liraglutide (Saxenda) about 5.0%, and naltrexone/bupropion about 4.6% in placebo-subtracted terms.12PubMed Central. Medications for obesity management: Effectiveness and value A large network meta-analysis of randomized trials confirmed the hierarchy, with semaglutide producing about 9 kg of weight loss beyond placebo at 12 months and phentermine/topiramate about 8 kg, while naltrexone/bupropion fell behind both.13PubMed. Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials
Those numbers might make naltrexone/bupropion look like a poor choice, but context matters. It is an oral pill, not an injection. It is generally cheaper than the GLP-1 drugs, which have been plagued by supply shortages and high out-of-pocket costs. And its mechanism of action targets reward-driven eating specifically, which may make it a better fit for people whose weight problem is rooted more in craving and compulsive eating than in hunger volume.
Effects on Binge Eating and Craving
The appetite effects of naltrexone-based treatments are especially pronounced in people who struggle with binge eating or reward-driven overeating. In a laboratory study of people with binge-eating disorder, naltrexone/bupropion significantly reduced the number of calories consumed when participants were presented with preferred high-calorie snacks. After six weeks of treatment, calorie intake dropped by over 1,100 calories compared to placebo in the laboratory setting, and sweet-food cravings decreased significantly during the period when food was available. Hunger ratings also fell.14Drug and Alcohol Dependence Reports. Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms
Earlier work using naloxone, a shorter-acting opioid antagonist closely related to naltrexone, found similar patterns. Naloxone reduced taste preferences for sweet, high-fat foods in both binge eaters and controls, and it significantly cut total snack intake in binge eaters, with the biggest reductions for cookies and chocolate.15Physiology & Behavior. Taste responses and preferences for sweet high-fat foods: Evidence for opioid involvement A pilot study in women with obesity found that while naltrexone at 25 mg and 50 mg did not reduce average craving intensity across all participants, the 50 mg dose specifically weakened the link between reward-based eating drive and craving intensity, meaning people who were most prone to reward-driven eating saw the greatest blunting of their cravings.16PubMed Central. Putting the brakes on the “drive to eat”: Pilot effects of naltrexone and reward based eating on food cravings among obese women
This last point is worth emphasizing. Naltrexone’s appetite effects are not uniform. They seem to scale with how reward-driven your eating behavior already is. If you overeat mostly because you are genuinely hungry or because of portion-size habits, naltrexone may do relatively little. If you overeat because certain foods light up your brain’s reward circuits in ways you find hard to resist, naltrexone is more likely to make a noticeable difference.
Side Effects and Safety Profile
Nausea is the most commonly reported side effect of naltrexone/bupropion. In the clinical trials, about 31% of people on the drug reported nausea compared to about 7% on placebo.17PubMed Central. Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes The nausea tends to be worst in the first few weeks and typically fades. This is why the recommended dosing starts low and escalates over a month. People who experienced nausea were also more likely to report vomiting, headache, dizziness, and diarrhea, though severe vomiting affected less than 1% of participants. One piece of reassurance from the data: weight loss in the trials was not simply a byproduct of nausea making people eat less. People who never experienced nausea still lost weight on the drug.17PubMed Central. Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
Other side effects are mostly attributable to the bupropion component, including a small risk of seizures. The drug should not be used in people with seizure disorders, those taking opioid medications, or anyone with uncontrolled hypertension. On the cardiovascular front, a large trial of nearly 9,000 participants with cardiovascular risk factors found that major adverse cardiovascular events occurred in about 2.0% of the drug group and 2.3% of the placebo group, a difference that was not statistically significant.18JAMA. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors Blood pressure rose by a small amount, roughly 1 mm Hg more than placebo. A real-world observational study comparing naltrexone/bupropion to another weight-loss medication found no elevated risk of heart attack or stroke.19Obesity Pillars. Cardiovascular safety of fixed-dose extended-release naltrexone/bupropion in clinical practice That said, long-term cardiovascular safety has not been definitively established for this drug class, and the same is true for most approved obesity medications.20PubMed Central. The risk of cardiovascular complications with current obesity drugs
People Who May Benefit Most
Because naltrexone targets opioid-mediated reward pathways, it can be useful for people whose weight issues overlap with other reward-driven behaviors. People with alcohol use disorder, for instance, already take naltrexone as a treatment for drinking. The neurobiological overlap between compulsive eating and compulsive drinking is substantial, and clinical observations suggest that naltrexone’s appetite-reducing effects in people with alcohol problems are consistent with this shared brain circuitry.21Molecular Psychiatry. Crosstalk between alcohol use disorder and obesity: two sides of the same coin? For someone dealing with both excess drinking and overeating, naltrexone can potentially address both issues with a single medication.
Women with polycystic ovary syndrome represent another group that has been studied. Several trials have found that naltrexone can reduce fasting insulin and insulin response to glucose in women with PCOS who have elevated insulin levels, though results across studies have been inconsistent. Some studies found a reduction in BMI, while others did not.22PubMed Central. Medical management of metabolic dysfunction in PCOS The insulin-lowering effect appears to depend on whether the patient already has elevated insulin; women with normal insulin levels showed no change.23PubMed. Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients The evidence here is not strong enough to recommend naltrexone specifically for PCOS-related weight management, but it is an area where the drug’s effects go beyond simple appetite suppression.
Genetics and Predicting Who Responds
Not everyone responds equally to naltrexone/bupropion, and emerging research suggests that genetics play a role. A pilot study looked at a well-known genetic variant near the dopamine D2 receptor gene called the Taq1A polymorphism. People who carried at least one copy of the A1 variant lost an average of about 5.9% of their body weight on naltrexone/bupropion, which was significantly greater than a predefined clinical threshold. Those without the A1 variant lost about 4.2%, a difference that did not clear the same threshold.24Europe PMC. Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. The A1 variant has previously been associated with reduced dopamine receptor density in the brain, which may make people more sensitive to reward-based interventions.
This is still early-stage work with a small sample, so it would be premature to recommend genetic testing before starting the medication. But it points toward a future where clinicians could match people to obesity drugs based on their neurobiological profile rather than just their BMI. If you carry a dopamine-receptor variant that makes you more prone to reward-driven eating, a drug that targets the reward pathway may work better for you than one that targets satiety signals or gut hormones.
What About Adolescents?
Most of the clinical trial data for naltrexone/bupropion comes from adults. The evidence base for adolescents is thin. A review of obesity pharmacotherapy in youth noted the urgent need for more effective treatment strategies and acknowledged that knowledge gaps persist for most weight-loss medications in younger populations.25PubMed Central. Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity Naltrexone/bupropion is not currently approved for use in people under 18. Some clinicians prescribe it off-label in adolescents with severe obesity, but doing so rests on extrapolation from adult data and individual clinical judgment rather than dedicated pediatric trials. If you’re considering this medication for a teenager, the honest answer is that the safety and efficacy data simply are not there yet.
Practical Tips for People Starting Naltrexone/Bupropion
The dosing schedule matters more than most people realize. The manufacturer recommends starting with one tablet per day and gradually increasing to two tablets twice daily over the course of a month.11PubMed Central. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives This slow ramp-up exists because bupropion can increase seizure risk and blood pressure when introduced abruptly, and it helps minimize the nausea that discourages many people from continuing.
A few other practical considerations:
- Opioid medications: You cannot take naltrexone if you are currently using any opioid pain medication, because naltrexone will block the opioid and could precipitate withdrawal. This includes prescription painkillers, certain cough medicines, and medications for opioid use disorder like methadone or buprenorphine.
- Alcohol: While naltrexone is used to treat alcohol use disorder, combining naltrexone/bupropion with heavy drinking increases the risk of seizures from the bupropion component.
- Response timeline: If you have not lost at least 5% of your body weight after 12 to 16 weeks at the full dose, guidelines generally recommend discontinuing the medication, as continued use is unlikely to produce meaningful additional loss.
- Weight regain: Like all current obesity medications, naltrexone/bupropion works while you take it. Stopping the medication often leads to weight regain, which is consistent with the understanding of obesity as a chronic condition requiring ongoing management rather than a one-time fix.
Low-Dose Naltrexone and Weight Loss
You may have encountered claims about low-dose naltrexone (LDN), typically in the range of 1.5 to 4.5 mg, for weight loss and various other conditions. Standard naltrexone dosing for obesity runs from 16 to 32 mg per day, so LDN operates at a fraction of the therapeutic opioid-blocking dose. The theory behind LDN is that at very low doses, naltrexone briefly blocks opioid receptors and then triggers a rebound increase in endorphin production, which proponents claim has anti-inflammatory and immune-modulating effects.
There is very little rigorous clinical trial evidence supporting LDN for weight loss specifically. Most of the published work on LDN involves small studies in conditions like fibromyalgia and Crohn’s disease, not obesity. Some people report reduced appetite and cravings on LDN, but these reports are largely anecdotal, and the mechanism would be quite different from the full-dose approach supported by the trial data described above. If you’re interested in naltrexone for weight management, the evidence-based version is the full-dose combination with bupropion, not the low-dose formulation that circulates in wellness communities.